Effect of co-administration of pranoprofen/emedastine difumarate eye drops on efficacy, inflammatory factors, tear film stability and immune function in children with allergic conjunctivitis

IF 0.6 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Shasha Zhang, Leiyan Su, Zefeng Kang, Shoukang Zhang, Jing Wang
{"title":"Effect of co-administration of pranoprofen/emedastine difumarate eye drops on efficacy, inflammatory factors, tear film stability and immune function in children with allergic conjunctivitis","authors":"Shasha Zhang, Leiyan Su, Zefeng Kang, Shoukang Zhang, Jing Wang","doi":"10.4314/tjpr.v22i7.20","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate the clinical efficacy of pranoprofen eye drops when combined with emedastinedifumarate eye drops for the treatment of children with allergic conjunctivitis.Methods: A total of 96 children with allergic conjunctivitis admitted to Eye Hospital, China Academy of Chinese Medical Sciences from January 2020 to 2022 were enrolled in this study. They were divided into study group (treated with both pranoprofen eye drops and emedastine difumarate eye drops), and control group (treated with emedastine difumarate eye drops alone), with 48 children in each group. The control group was given emedastine fumarate eye drops 1 drop twice a day. The study group was given pranoprofen eye drops 2 drops 4 times a day in addition to the treatment administered to control group. Patients in both groups were observed and compared after one week of treatment. Efficacy, incidence of adverse reactions, symptom scores, inflammatory factors, tear film stability indicators and immune function indicators were assessed and recorded.Results: Prior to treatment, there was no significant difference in symptom score, inflammatory factors, tear film stability indicators and immune function indicators between study and control groups. Although the above indicators improved in both groups after treatment, the study group showed significantly greater improvement than control group (p < 0.05). Overall clinical response rate in the study group (95.83 %) was higher than in the control group (77.08 %), while the incidence of adverse reaction in the study group (6.25 %) was lower than that of control group (27.08 %, p < 0.05).Conclusion: Pranoprofen eye drops, when combined with emedastine difumarate eye drops for treatment of children with allergic conjunctivitis, is more effective than the use of emedastine difumarate eye drops alone. However, further clinical trials are required to validate the findings of this study prior to adoption of the combination treatment in clinical practice.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"76 1","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2023-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tropical Journal of Pharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4314/tjpr.v22i7.20","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To investigate the clinical efficacy of pranoprofen eye drops when combined with emedastinedifumarate eye drops for the treatment of children with allergic conjunctivitis.Methods: A total of 96 children with allergic conjunctivitis admitted to Eye Hospital, China Academy of Chinese Medical Sciences from January 2020 to 2022 were enrolled in this study. They were divided into study group (treated with both pranoprofen eye drops and emedastine difumarate eye drops), and control group (treated with emedastine difumarate eye drops alone), with 48 children in each group. The control group was given emedastine fumarate eye drops 1 drop twice a day. The study group was given pranoprofen eye drops 2 drops 4 times a day in addition to the treatment administered to control group. Patients in both groups were observed and compared after one week of treatment. Efficacy, incidence of adverse reactions, symptom scores, inflammatory factors, tear film stability indicators and immune function indicators were assessed and recorded.Results: Prior to treatment, there was no significant difference in symptom score, inflammatory factors, tear film stability indicators and immune function indicators between study and control groups. Although the above indicators improved in both groups after treatment, the study group showed significantly greater improvement than control group (p < 0.05). Overall clinical response rate in the study group (95.83 %) was higher than in the control group (77.08 %), while the incidence of adverse reaction in the study group (6.25 %) was lower than that of control group (27.08 %, p < 0.05).Conclusion: Pranoprofen eye drops, when combined with emedastine difumarate eye drops for treatment of children with allergic conjunctivitis, is more effective than the use of emedastine difumarate eye drops alone. However, further clinical trials are required to validate the findings of this study prior to adoption of the combination treatment in clinical practice.
普萘洛芬/艾美司汀双富马酸滴眼液对变应性结膜炎患儿疗效、炎症因子、泪膜稳定性及免疫功能的影响
目的:探讨普萘洛芬滴眼液联合咪达司丁滴眼液治疗儿童变应性结膜炎的临床疗效。方法:选取2020年1月至2022年1月在中国中医科学院眼科医院住院的96例过敏性结膜炎患儿为研究对象。将患儿分为研究组(同时使用普萘洛芬滴眼液和双富马酸艾美司汀滴眼液)和对照组(单独使用双富马酸艾美司汀滴眼液),每组48例。对照组患者给予富马酸埃米司汀滴眼液1滴,每日2次。实验组患者在对照组治疗的基础上给予普萘洛芬滴眼液2滴,每日4次。治疗1周后对两组患者进行观察比较。评估并记录两组患者的疗效、不良反应发生率、症状评分、炎症因子、泪膜稳定性指标及免疫功能指标。结果:治疗前,实验组与对照组在症状评分、炎症因子、泪膜稳定性指标、免疫功能指标上均无显著差异。治疗后两组患者上述指标均有所改善,但研究组改善程度明显高于对照组(p < 0.05)。研究组临床总有效率(95.83%)高于对照组(77.08%),不良反应发生率(6.25%)低于对照组(27.08%,p < 0.05)。结论:普萘洛芬滴眼液联合艾美司汀滴眼液治疗儿童变应性结膜炎的疗效优于单用艾美司汀滴眼液。然而,在临床实践中采用联合治疗之前,需要进一步的临床试验来验证本研究的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
33.30%
发文量
490
审稿时长
4-8 weeks
期刊介绍: We seek to encourage pharmaceutical and allied research of tropical and international relevance and to foster multidisciplinary research and collaboration among scientists, the pharmaceutical industry and the healthcare professionals. We publish articles in pharmaceutical sciences and related disciplines (including biotechnology, cell and molecular biology, drug utilization including adverse drug events, medical and other life sciences, and related engineering fields). Although primarily devoted to original research papers, we welcome reviews on current topics of special interest and relevance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信